VIVANI MED.INC. NEW O.N. (U5P) - Net Assets
Based on the latest financial reports, VIVANI MED.INC. NEW O.N. (U5P) has net assets worth €15.73 Million EUR (≈ $18.39 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€39.39 Million ≈ $46.05 Million USD) and total liabilities (€23.66 Million ≈ $27.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of VIVANI MED.INC. NEW O.N. for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €15.73 Million |
| % of Total Assets | 39.93% |
| Annual Growth Rate | 58.94% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 746.62 |
VIVANI MED.INC. NEW O.N. - Net Assets Trend (2021–2025)
This chart illustrates how VIVANI MED.INC. NEW O.N.'s net assets have evolved over time, based on quarterly financial data. Check VIVANI MED.INC. NEW O.N. (U5P) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for VIVANI MED.INC. NEW O.N. (2021–2025)
The table below shows the annual net assets of VIVANI MED.INC. NEW O.N. from 2021 to 2025. For live valuation and market cap data, see U5P stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €15.73 Million ≈ $18.39 Million |
-10.68% |
| 2024-12-31 | €17.61 Million ≈ $20.59 Million |
-15.18% |
| 2023-12-31 | €20.76 Million ≈ $24.27 Million |
-53.14% |
| 2022-12-31 | €44.31 Million ≈ $51.80 Million |
+1697.48% |
| 2021-12-31 | €2.46 Million ≈ $2.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to VIVANI MED.INC. NEW O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8963600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €164.26 Million | 1044.27% |
| Total Equity | €15.73 Million | 100.00% |
VIVANI MED.INC. NEW O.N. Competitors by Market Cap
The table below lists competitors of VIVANI MED.INC. NEW O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vera Bradley Inc
NASDAQ:VRA
|
$79.34 Million |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
$79.39 Million |
|
Appeninn Vagyonkezelo Holding Nyilvanosan Mukodo Reszvenytarsasag
F:0AP
|
$79.41 Million |
|
Azaria Rental SOCIMI S.A.
MC:YAZR
|
$79.42 Million |
|
Thai Rung Union Car Public Company Limited
BK:TRU
|
$79.31 Million |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
$79.29 Million |
|
Ba Ria Vung Tau House Development JSC
VN:HDC
|
$79.28 Million |
|
VirnetX Holding Corp Common Stock
NYSE:VHC
|
$79.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VIVANI MED.INC. NEW O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,610,000 to 15,730,000, a change of -1,880,000 (-10.7%).
- Net loss of 26,609,000 reduced equity.
- Share repurchases of 28,000 reduced equity.
- New share issuances of 23,291,000 increased equity.
- Other factors increased equity by 1,466,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-26.61 Million | -169.16% |
| Share Repurchases | €28.00K | -0.18% |
| Share Issuances | €23.29 Million | +148.07% |
| Other Changes | €1.47 Million | +9.32% |
| Total Change | €- | -10.68% |
Book Value vs Market Value Analysis
This analysis compares VIVANI MED.INC. NEW O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.25x to 5.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.05 | €1.13 | x |
| 2022-12-31 | €0.87 | €1.13 | x |
| 2023-12-31 | €0.41 | €1.13 | x |
| 2024-12-31 | €0.30 | €1.13 | x |
| 2025-12-31 | €0.21 | €1.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VIVANI MED.INC. NEW O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -169.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.50x
- Recent ROE (-169.16%) is above the historical average (-195.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -518.17% | 0.00% | 0.00x | 2.21x | €-13.02 Million |
| 2022 | -31.35% | 0.00% | 0.00x | 1.15x | €-18.32 Million |
| 2023 | -123.56% | 0.00% | 0.00x | 2.21x | €-27.73 Million |
| 2024 | -133.37% | 0.00% | 0.00x | 2.36x | €-25.25 Million |
| 2025 | -169.16% | 0.00% | 0.00x | 2.50x | €-28.18 Million |
Industry Comparison
This section compares VIVANI MED.INC. NEW O.N.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,318,144,326
- Average return on equity (ROE) among peers: -6.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VIVANI MED.INC. NEW O.N. (U5P) | €15.73 Million | -518.17% | 1.50x | $79.34 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $41.39 Million | -67.94% | 2.33x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $242.58 Million | -85.63% | 0.52x | $206.86 Million |
| PreveCeutical Medical Inc (18H) | $-4.10 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.06 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-2.33 Million | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $20.06 Billion | 47.04% | 0.16x | $20.05 Billion |
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more